You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Developing a Point of CarePOCLateral Flow AssayLFAto Detect Taenia Solium

    SBC: APTAGEN LLC            Topic: ODCDC

    Taenia solium is a parasite acquired by pigs and transmitted to humans by eating or mishandling raw or undercooked infected porkIncidences primarily occur in areas with subsistence farming practices such as sub Saharan AfricaLatin Americaand AsiaIt affectsmillion people globallyCases of cystercercosis have been seen in the US and Canada due to globalizationIngested Taeniasolium oncospheres can mig ...

    SBIR Phase II 2019 Department of Health and Human ServicesCenters for Disease Control and Prevention
  2. A Novel Synthetic Vascular Graft Capable of Minimally Invasive Controlled Expansion for Vascular Reconstruction Model

    SBC: PECA LABS INC            Topic: NHLBI

    PROJECT SUMMARY In pediatric cardiovascular surgery, no commercially available vascular conduit is capable of growing with the patient following implantation. This inability to grow with the patient is particularly relevant for newborns and young children because additional surgeries are required to replace the implanted conduit. In order to address this issue, PECA Labs has developed a novel card ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Advancing and calibrating anisotropic diffusion MR imaging brain connectome with Taxon brain network diffusion phantoms

    SBC: Psychology Software Tools, Inc.            Topic: 106

    There is a critical gap in the reliability of anisotropic diffusion magnetic resonance imaging (AdMRI). This gap can be filled by using a ground truth measurement capability that allows for the necessary parametric control of water filled geometries of tubes at the micron scale that can produce paths representative of the millions of axons across centimeters in brain tract trajectories. Diffusion ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NHLBI

    We have discovered the first-ever inhibitors of PF4, a platelet protein central to the pathophysiology of heparin induced thrombocytopenia (HIT). Heparin is a naturally-occurring anticoagulant that prevents the formation of clots and extension of existing clots within the vasculature, and major medical applications of heparin include dialysis, cardiac catheterization, and cardiopulmonary bypass su ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Medical Device Utilizing an EEG-Based Algorithm for the Objective Quantification of Pain

    SBC: PAINQX INC            Topic: NIDA

    Project Summary / Abstract Chronic pain affects over 100 million Americans representing a major public health imperative. Objective biomarkers of pathology exist for several diseases, and their development is one of the great advances of modern allopathic medicine; however, objective assessment of pain has lagged far behind. Currently, there are no objectively verifiable and clinically useful mean ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. A Single-Cell Proteomic instrument for Predictive Product Quality Check in Autologous CAR-T Immunotherapies

    SBC: ISOPLEXIS CORPORATION            Topic: 102

    While CAR-T therapies have advanced in the clinic, there are still two specific issues using these breakthrough therapies for blood cancers: Durable responses in patients are only at 30-50% and Cytokine Release Syndrome occurs in 60-90% of treated patients. These limitations, for a drug that costs as much as $500,000, may cost an additional $250,000+ for treating adverse events leading to caution ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. System and comprehensive approach for blood compatibility of medical devices and biomaterial

    SBC: ENSION Inc            Topic: NHLBI

    AbstractTo dateblood compatibility testing of biomaterials and medical devices has not led to a consensus on what materials are non thrombogenic nor has it advanced understanding of what and how variables and responses can be measured in vitro to begin to predict in vivo performanceWhile ISOidentifies five categories of responses that should be consideredthrombosiscoagulationplateletsleukocyte act ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of GPER Agonists as Cancer Therapeutics

    SBC: Linnaeus Therapeutics LLC            Topic: 102

    Project summary: This project is designed to evaluate a new class of anti-cancer agents for treatment of invasive melanoma, pancreas, lung, and colon carcinomas. The study compounds are small, synthetic molecules that have not previously been used in people, and bind to a surface receptor, G protein- coupled estrogen receptor (GPER) on tumor cells that has not previously been targeted in cancer. S ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Advancement of antiviral inhibitors of chikungunya virus

    SBC: VENATORX PHARMACEUTICALS INC            Topic: NIAID

    PROJECT SUMMARY Novel therapies for the treatment of chikungunya virus (CHIKV) infections are urgently needed to address the alarming spread of this pathogen across the Americas. We have identified three distinct series of potent, selective, and orally bioavailable inhibitors of CHIKV replication. In this Phase II renewal SBIR project, we will optimize these series of CHIKV inhibitors to Pre-Devel ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Product for sensitive imaging of cells in vivo

    SBC: CELSENSE, INC.            Topic: NIBIB

    In this Phase 2 application we aim to continue development and commercialization of a novel and sensitive magnetic resonance imaging (MRI) probe for the cell therapy tools market. We propose to implement first-into- man clinical translation of this technology to visualize the trafficking of tumor infiltrating lymphocytes (TILs) in head and neck cancer (HNC) patients. Celsense, Inc., manufactures i ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government